US HR1125 | 2019-2020 | 116th Congress

Status

Spectrum: Partisan Bill (Democrat 23-0)
Status: Introduced on September 18 2020 - 25% progression, died in committee
Action: 2020-09-18 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]

Summary

This resolution expresses the sense of the House of Representatives that federal agencies should take appropriate actions to (1) ensure meaningful engagement of communities of color in the conduct of COVID-19 (i.e., coronavirus disease 2019) research and participation in clinical trials, and (2) improve equitable access to safe and effective vaccines.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.

Sponsors


History

DateChamberAction
2020-09-18HouseReferred to the House Committee on Energy and Commerce.
2020-09-18HouseIntroduced in House

Subjects


US Congress State Sources


Bill Comments

feedback